(0.33%) 5 116.99 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.99%) $83.02
(5.56%) $2.03
(0.34%) $2 355.20
(0.46%) $27.66
(4.05%) $959.45
(-0.26%) $0.932
(-0.43%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases...
Stats | |
---|---|
本日の出来高 | 23.92M |
平均出来高 | 0.00 |
時価総額 | 26.63B |
EPS | $1.250 ( 2023-11-01 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 61.86 |
ATR14 | $0.803 (0.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-06 | Watkins Thomas | Sell | 10 000 | Ordinary Shares |
2023-10-06 | Watkins Thomas | Sell | 8 548 | Stock Option (Right to Buy) |
2023-10-06 | Watkins Thomas | Sell | 23 092 | Stock Option (Right to Buy) |
2023-10-06 | Watkins Thomas | Sell | 31 153 | Stock Option (Right to Buy) |
2023-10-06 | Watkins Thomas | Sell | 10 838 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-89.06 |
Last 100 transactions |
Buy: 244 079 | Sell: 3 988 089 |
ボリューム 相関
Horizon Therapeutics PLC 相関
10 最も負の相関 | |
---|---|
GAINL | -0.964 |
QTEK | -0.96 |
FATE | -0.959 |
LNSR | -0.957 |
IMCC | -0.953 |
VS | -0.95 |
QLGN | -0.949 |
WISA | -0.947 |
TOPS | -0.945 |
LHDX | -0.945 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Horizon Therapeutics PLC 相関 - 通貨/商品
Horizon Therapeutics PLC 財務諸表
Annual | 2022 |
収益: | $3.63B |
総利益: | $2.71B (74.64 %) |
EPS: | $2.28 |
FY | 2022 |
収益: | $3.63B |
総利益: | $2.71B (74.64 %) |
EPS: | $2.28 |
FY | 2021 |
収益: | $3.23B |
総利益: | $2.43B (75.37 %) |
EPS: | $2.37 |
FY | 2020 |
収益: | $2.20B |
総利益: | $1.67B (75.79 %) |
EPS: | $1.910 |
Financial Reports:
No articles found.
Horizon Therapeutics PLC
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。